Demographics and clinical characteristics of enrolled patients at baseline
| Parameters . | IQ (n = 23) . | Placebo (n = 23) . |
|---|---|---|
| n (%) . | n (%) . | |
| Age (y) | 43 ± 12 | 38 ± 12 |
| Body mass index (kg/m2)∗ | 26.1 ± 4.9 | 24.4 ± 3.2 |
| Sex† | ||
| Female | 12 (52) | 14 (61) |
| Male | 11 (48) | 9 (39) |
| Genotype† | ||
| SS | 18 (78) | 22 (96) |
| Others | 5 (23) | 1 (4) |
| Race† | ||
| Black or African American | 21 (91) | 21 (95.5) |
| Multiple races | 2 (9) | 1 (4.5) |
| Ethnicity† | ||
| Non-Latino or Hispanic | 22 (96) | 19 (86.5) |
| Latino or Hispanic | 1 (4) | 2 (9) |
| Unknown | 0 | 1 (4.5) |
| History of VTE and VOC† | ||
| VOCs (per year for the past 3 y) | 3 (14) | 3 (14) |
| VTE | 5 (26) | 8 (36) |
| Therapy | ||
| Hydroxyurea | 18 (78) | 18 (82) |
| DOACs | 2 (9) | 2 (9) |
| Aspirin | 3 (13) | 3 (13.6) |
| Hematological parameters∗ | ||
| Hb (g/dL) | 8.9 ± 1.4 | 8.8 ± 1.6 |
| HbS (%) | 72.6 ± 13.8 | 77.9 ± 9.0 |
| HbF (%) | 11.1 ± 11.3 | 15.3 ± 9.9 |
| Reticulocytes (103/μL) | 217.8 ± 108.8 | 174 ± 124 |
| Neutrophils (103/μL) | 4.2 ± 2.0 | 4.0 ± 2.0 |
| Monocytes (103/μL) | 0.6 ± 0.7 | 0.6 ± 0.3 |
| Platelets (103/μL) | 217.8 ± 111.2 | 354.1 ± 120 |
| Biochemical parameters∗ | ||
| hsCRP (mg/L) | 7.5 ± 5.8 | 6.0 ± 6.0 |
| LDH (U/L) | 392 ± 172 | 404 ± 135 |
| Bilirubin total (mg/dL) | 2.6 ± 2.0 | 2.5 ± 1.6 |
| Biomarkers of thrombotic risk∗ | ||
| sP-selectin (ng/mL) | 30 ± 9.9 | 32 ± 8.3 |
| D-dimer (μg/mL)‡ | 1.5 ± 0.8 | 1.9 ± 2.3 |
| TAT (ng/mL)‡ | 2.7 ± 1.4 | 2.5 ± 0.9 |
| Parameters . | IQ (n = 23) . | Placebo (n = 23) . |
|---|---|---|
| n (%) . | n (%) . | |
| Age (y) | 43 ± 12 | 38 ± 12 |
| Body mass index (kg/m2)∗ | 26.1 ± 4.9 | 24.4 ± 3.2 |
| Sex† | ||
| Female | 12 (52) | 14 (61) |
| Male | 11 (48) | 9 (39) |
| Genotype† | ||
| SS | 18 (78) | 22 (96) |
| Others | 5 (23) | 1 (4) |
| Race† | ||
| Black or African American | 21 (91) | 21 (95.5) |
| Multiple races | 2 (9) | 1 (4.5) |
| Ethnicity† | ||
| Non-Latino or Hispanic | 22 (96) | 19 (86.5) |
| Latino or Hispanic | 1 (4) | 2 (9) |
| Unknown | 0 | 1 (4.5) |
| History of VTE and VOC† | ||
| VOCs (per year for the past 3 y) | 3 (14) | 3 (14) |
| VTE | 5 (26) | 8 (36) |
| Therapy | ||
| Hydroxyurea | 18 (78) | 18 (82) |
| DOACs | 2 (9) | 2 (9) |
| Aspirin | 3 (13) | 3 (13.6) |
| Hematological parameters∗ | ||
| Hb (g/dL) | 8.9 ± 1.4 | 8.8 ± 1.6 |
| HbS (%) | 72.6 ± 13.8 | 77.9 ± 9.0 |
| HbF (%) | 11.1 ± 11.3 | 15.3 ± 9.9 |
| Reticulocytes (103/μL) | 217.8 ± 108.8 | 174 ± 124 |
| Neutrophils (103/μL) | 4.2 ± 2.0 | 4.0 ± 2.0 |
| Monocytes (103/μL) | 0.6 ± 0.7 | 0.6 ± 0.3 |
| Platelets (103/μL) | 217.8 ± 111.2 | 354.1 ± 120 |
| Biochemical parameters∗ | ||
| hsCRP (mg/L) | 7.5 ± 5.8 | 6.0 ± 6.0 |
| LDH (U/L) | 392 ± 172 | 404 ± 135 |
| Bilirubin total (mg/dL) | 2.6 ± 2.0 | 2.5 ± 1.6 |
| Biomarkers of thrombotic risk∗ | ||
| sP-selectin (ng/mL) | 30 ± 9.9 | 32 ± 8.3 |
| D-dimer (μg/mL)‡ | 1.5 ± 0.8 | 1.9 ± 2.3 |
| TAT (ng/mL)‡ | 2.7 ± 1.4 | 2.5 ± 0.9 |